

# Detection and treatment of congenital hypothyroidism

Annette Grüters and Heiko Krude

**Abstract** | Congenital hypothyroidism is the most frequent endocrine disorder in neonates. Controversy exists regarding the necessity to adjust current screening programs to also diagnose patients with central hypothyroidism or those with mild forms of congenital hypothyroidism, who have high TSH levels but normal  $T_4$  and normal  $T_3$  levels (also known as ‘subclinical hypothyroidism’). Thyroid hormone replacement should start as soon as the diagnosis is confirmed by measurement of elevated TSH and low serum thyroid hormone levels. Further diagnostic approaches, such as ultrasonography, scintigraphy and measurement of thyroglobulin levels, to determine the subtype of congenital hypothyroidism, should not delay initiation of treatment. Recommendations regarding the initial dosage of levothyroxine vary considerably, and no general accepted guideline exists with regards to initial dosage or optimal time point for dose adjustment according to biochemical parameters. More than 30 years after the introduction of the first neonatal screening programs, mental retardation can be prevented in the majority of children (>90%) with congenital hypothyroidism if therapy is commenced within the first 2 weeks of life, making neonate screening for this disorder the most successful population-based screening test in pediatrics.

Grüters, A. & Krude, H. *Nat. Rev. Endocrinol.* advance online publication 18 October 2011; doi:10.1038/nrendo.2011.160

## Introduction

The term ‘congenital hypothyroidism’ was introduced more than 60 years ago when Radwin *et al.* first described children with hypothyroid-associated features of severe intellectual disability and growth retardation.<sup>1</sup> Today, this definition of congenital hypothyroidism has to be revisited, as the diagnosis of the disease is made before the onset of severe clinical symptoms, on the basis of biochemical measurement of TSH and thyroid hormone levels alone.<sup>2,3</sup>

Primary congenital hypothyroidism, the most common form of congenital hypothyroidism, occurs as a result of developmental defects of the thyroid gland, known as thyroid agenesis or dysgenesis, or is due to disruptions in thyroid hormone biosynthesis, also known as thyroid dyshormonogenesis. In the majority (80%) of cases, a structural defect of the thyroid gland is present: an ectopic gland in a cranial, sometimes lingual, position; thyroid gland hypoplasia; or the complete absence of thyroid tissue.<sup>4–6</sup> Minor variants of thyroid dysgenesis include the absence of the thyroid isthmus or a lack of one—in most cases the left-lobe of the thyroid. This thyroid hemiagenesis can be found with a frequency of 1 in 1,000–2,000 individuals without a pre-existing diagnosis of hypothyroidism;<sup>7</sup> its finding in children with neonatally elevated levels of TSH, therefore, does not confirm the diagnosis of congenital hypothyroidism. In the remaining 20% of children with congenital hypothyroidism, a normal or enlarged thyroid can be identified. These children are affected by

a defect of thyroid hormone synthesis, which occurs in most cases as an autosomal recessive trait of inheritance. Secondary congenital hypothyroidism, also termed central congenital hypothyroidism, is caused by deficiencies in TSH, for example, in patients with pituitary insufficiency or structural abnormalities of the pituitary gland or hypothalamus.

Over time, TSH cut-off levels used in confirmatory diagnoses have been lowered, leading to the diagnosis of congenital hypothyroidism in patients who exhibit elevated TSH levels without decreased peripheral thyroid hormone concentrations or clinical symptoms. This mild form of congenital hypothyroidism occurs as the result of either a transient or permanent rise in TSH levels and has been named ‘subclinical hypothyroidism’. However, given that this condition does not reflect a true state of hypothyroidism, nor causes an obvious developmental defect, this form would be more accurately labeled as ‘hyperthyrotropinemia’.

The purpose of this Review is to summarize the current knowledge on the etiology underlying thyroid dysgenesis and dyshormonogenesis and to provide an update on the evidence concerning the diagnosis and treatment of patients with congenital hypothyroidism.

## Neonatal screening

Klein and co-workers first showed that the IQ of a child with congenital hypothyroidism dramatically depends on the time of clinical diagnosis and initiation of replacement therapy.<sup>8</sup> Only diagnosis and treatment before the age of 3 months enables normal mental development, an

## Competing interests


The authors declare no competing interests.

Institute of Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Augustenburgerplatz 1, D-13353 Berlin, Germany (A. Grüters, H. Krude).

Correspondence to: A. Grüters [annette.grueters@charite.de](mailto:annette.grueters@charite.de)

**Key points**

- Neonatal screening for primary congenital hypothyroidism is an efficient tool for the secondary prevention of severe mental retardation
- Diagnosis of primary congenital hypothyroidism is based on detection of an increased TSH concentration in the presence of low T<sub>4</sub> levels in serum
- The differential diagnosis of congenital hypothyroidism includes defects of thyroid hormone synthesis in patients with a normal thyroid gland or goiter and several diseases arising from thyroid transcription factor defects in patients with thyroid dysgenesis
- Although evidence for particular treatment modalities was not generated in prospective controlled studies, an initial daily dose of >10 µg levothyroxine per kg of body weight is recommended to treat congenital hypothyroidism



**Figure 1** | Congenital hypothyroidism due to thyroid dysgenesis. **a** | The three different forms of thyroid dysgenesis are shown: complete absence of the thyroid gland, ectopic gland and thyroid hypoplasia. The first and second images were obtained by scintigraphy, the third by ultrasonography. **b** | Different steps of the embryonic development of the thyroid gland in mice embryos, as shown in 3D reconstructions. Green marks the endodermal pharynx from which the thyroid primordium (in gray) is budding at day 10 of mouse development. The thyroid bud keeps in contact with the arteries of the heart outflow tract (in red) until later stages, when the aortic arch develops further caudally into the mediastinum. The thyroid migrates back cranially and by lateralization builds the final lateral functional lobes of the gland at day 15, which corresponds to week 12 of human development. During these different steps of embryogenesis, several transcription-factor-encoding genes are continuously expressed, whereas the *TSHR* gene, as the other functional genes important for thyroid hormone synthesis, is only expressed during late stages of fetal development.

observation that led the researchers to propose the introduction of screening programs. Neonatal screening for congenital hypothyroidism became a feasible option only after the development of specific, robust and sensitive radioimmunoassays for TSH and T<sub>4</sub>.<sup>9</sup> Subsequently, the results of two pilot screening programs were published in the early 1970s.<sup>10,11</sup>

Owing to the transient rise of TSH in the first 48 h after birth,<sup>12</sup> either cord blood samples or dried blood spots taken from heel pricks after the third day of life were used to measure either TSH alone (Europe and Japan)<sup>3</sup> or T<sub>4</sub> followed by TSH in neonates with a T<sub>4</sub> concentration below the 10<sup>th</sup> percentile (North America).<sup>2</sup> Both strategies aimed to identify children with primary congenital hypothyroidism but not those with central congenital hypothyroidism. The results of these first screening programs were encouraging and confirmed that early diagnosis and treatment can offer a normal intellectual outcome in a disease that was historically thought to result in severe mental retardation.<sup>2,3</sup>

The incidence of congenital hypothyroidism that was observed in the first screening programs was similar, with a rate of 1 in 3,000–4,000, which was twofold higher than the incidence calculated by clinical diagnosis in the pre-screening era.<sup>13–17</sup> Further neonatal screening programs have confirmed an incidence of 1 in 3,500 in a wide range of different geographic and ethnic populations.<sup>18</sup> Two exceptions in US screening programs refer to Hispanic neonates, who exhibit an increased incidence of 1 in 2,000, and to neonates of African American origin, who show a reduced incidence of 1 in 10,000.<sup>19</sup> Interestingly, a female preponderance was observed in all screening cohorts, similar to that seen in cohorts studied before the introduction of screening.<sup>20</sup>

Over the past four decades, increasing overall incidence rates have been observed in the USA, without an obvious identifiable reason. Several factors have been proposed to underlie this increase: the diagnosis of more subtle cases of congenital hypothyroidism due to lower TSH cut-off levels; the increasing number of preterm children, who can be affected by a transient rise in TSH levels; and a change in study populations, with a higher proportion of neonates with a Hispanic background.<sup>21</sup>

**Etiology**

Insights into the pathogenesis of congenital hypothyroidism have revealed that genetic causes are detectable not only in patients with dys-hormonogenesis, but also in individual patients with developmental defects of the thyroid, which were previously regarded to have a noninherited sporadic disorder.<sup>22</sup> However, although molecular genetic testing can clarify the cause of dys-hormonogenesis in the majority of patients, the molecular basis of congenital hypothyroidism in those with thyroid dysgenesis remains predominantly unknown. Only few familial cases of thyroid dysgenesis have been reported to date,<sup>23</sup> and discordance is found even between monozygotic twins.<sup>24</sup> Nevertheless, in single cases of thyroid dysgenesis, inactivating mutations in transcription-factor-encoding genes expressed during thyroid organogenesis have been identified (Figure 1).<sup>22</sup> In addition, congenital hypothyroidism with normal localization of the thyroid gland or a goiter can reflect a recessively inherited defect of thyroid hormone synthesis (Figure 2). These rare mutations have clinical relevance, as they enable clinicians to provide genetic counseling, as well as adequate treatment and follow-up, for example because affected patients

with thyroid dysgenesis can manifest with more complex comorbidities. Nevertheless, in some patients with well-defined genetic defects, such as Down syndrome<sup>25</sup> or Williams–Beuren syndrome,<sup>26</sup> the molecular basis of the usually mild forms of congenital hypothyroidism or hyperthyrotropinemia remains to be identified.

### Mutations causing thyroid dysgenesis


Due to the low frequency of mutations in patients with thyroid dysgenesis,<sup>27,28</sup> genetic testing should be initiated only in those patients with either a suggestive clinical manifestation (*FOXE1*, *NKX2-1* and *NKX2-5* gene mutations) or with a familial occurrence of thyroid dysgenesis (*PAX8* and *TSHR* gene mutations).

#### *FOXE1*

At birth, the clinical diagnosis of a child with congenital hypothyroidism and thyroid dysgenesis associated with cleft palate and striking spiky hairs should suggest the diagnosis of the Bamforth–Lazarus syndrome,<sup>29</sup> which is caused by a mutation in the transcription-factor-encoding gene *FOXE1*.<sup>30,31</sup> These children have an unfavorable cognitive outcome despite adequate treatment of congenital hypothyroidism owing to the additional role of *FOXE1* in the development of the central nervous system (CNS). This prognosis, as well as the autosomal recessive mode of inheritance, should be addressed in genetic counseling.

#### *NKX2-1*

The majority of patients with mutations of the *NKX2-1* gene present with either mild or severe congenital hypothyroidism in association with variable pulmonary symptoms, as well as neurological alterations, such as severe choreoathetosis, ataxia and other movement disorders.<sup>32,33</sup> This particular association of symptoms results from the multiple roles of the *NKX2-1* transcription factor in the development and function of different organ systems, that is, the CNS, lung and thyroid. The phenotype of *NKX2-1*-deficient patients is variable, with no direct correlation of disease severity between these organ systems. Neonates and infants have died due to severe pulmonary insufficiency despite only mild hypothyroidism,<sup>34,35</sup> whereas other patients have severe motor defects but completely normal thyroid function and no pulmonary symptoms. Sequencing of the *NKX2-1* gene is recommended in neonates with elevated TSH levels and severe pulmonary complications or in children with congenital hypothyroidism and unfavorable motor development despite adequate treatment. In the first year of life, muscular hypotonia occurs, which is followed by the more specific movement defect of chorea (involuntary, irregular migrating contractions of the limbs) or athetosis (involuntary, convoluted writhing and twisting movements of the fingers, arms, legs and neck) during further motor development. During adolescence, the movement disorder does not deteriorate, and an improvement of chorea was observed in some adult patients.<sup>36</sup> Genetic counseling is based on the autosomal dominant inheritance; however, the relevance of counseling is very limited due to the variable penetrance of *NKX2-1* gene mutations within the three affected organ systems.



**Figure 2** | Thyroid hormone synthesis. The several levels of thyroid regulation by TRH and TSH as well as the functional steps of thyroid hormone production are shown. The key elements of thyroid hormone production are: transport of iodine through the thyroid cell into the thyroid follicular lumen; iodination of tyrosine rings of the matrix protein thyroglobulin in the follicular lumen by TPO and  $H_2O_2$  generated by the DUOX enzymatic system; joining of two iodinated tyrosine residues of thyroglobulin into the mature  $T_4$  molecule by TPO; transport of  $T_4$  through the thyroid cells into the circulation, most likely via  $T_4$  transporter molecules, which are not yet defined in detail. The whole process is activated by TSH, which is secreted from the pituitary gland under control of TRH, in response to thyroid hormone level. Abbreviations: DUOX, dual oxidase; NIS, sodium-iodide symporter; Tg, thyroglobulin; TPO, thyroid peroxidase; TRH, thyroid-releasing hormone; TSHR, TSH receptor.

#### *NKX2-5*

A very rare variant of congenital hypothyroidism due to mutations in the *NKX2-5* gene was described in four patients, of whom one was affected by an associated heart defect. Although heart defects account for 50% of all associated malformations in congenital hypothyroidism, only this one *NKX2-5* mutation has been reported to date.<sup>37</sup>

#### *PAX8*

Another example of a thyroid transcription factor defect that affects thyroid function and development is the *PAX8* gene mutation.<sup>38</sup> This defect in thyroid dysgenesis leads to a variable and potentially asymmetric hypoplasia of the thyroid gland. Hypothyroidism can be mild, and some patients manifest an elevation of TSH levels only later during childhood, thereby escaping the diagnosis by neonatal screening.<sup>38</sup> In addition to thyroid dysgenesis, *PAX8* gene mutations can also lead to unilateral kidney agenesis. Patients with a *PAX8* mutation should, therefore, undergo renal ultrasound investigation.<sup>39</sup> Although *PAX8* is also expressed in the brain and the ear anlage, no further defect or clinical symptom of the CNS has been described in *PAX8*-deficient patients.<sup>40</sup>

#### *TSHR*

Even before the description of thyroid dysgenesis caused by transcription factor defects, inactivating mutations of the

TSH receptor<sup>41</sup> were found to result in congenital hypothyroidism and thyroid dysgenesis with autosomal recessive inheritance. Because the encoding gene, *TSHR*, is expressed only late during fetal development, homozygous or compound heterozygous inactivating mutations lead to hypoplasia and not to an ectopic gland or agenesis of the gland. A less severe inactivation of the TSH receptor can also result in mildly elevated TSH levels with normal T<sub>4</sub> levels.<sup>42</sup>

#### Mutations causing thyroid dysmorphogenesis

Each step of the complex process of thyroid hormone synthesis, including iodine transport into the thyroid follicle (via the sodium-iodide symporter NIS and the sodium-independent chloride/iodide transporter pendrin<sup>43</sup>) and iodine incorporation into the nascent thyroid hormone (via the enzymes thyroid peroxidase [TPO],<sup>44</sup> dual oxidases [DUOX]<sup>45</sup> and the matrix protein thyroglobulin<sup>46</sup>) can be affected (Figure 2).

#### TPO and TG

Since the first description of an inactivating mutation in the *TPO* gene in 1992,<sup>47</sup> it was shown that in most children with thyroid dysmorphogenesis, a molecular inherited defect of thyroid hormone synthesis can be diagnosed. The partial or complete loss of activity of TPO or thyroglobulin (encoded by the *TG* gene) leads to severe hypothyroidism with a large goiter.

#### SLC26A4

The *SLC26A4* gene encodes pendrin, a protein expressed in follicular cells and in cells of the inner ear that transports iodine into the thyroid follicle. In children with mutations in this gene, an associated hearing loss can be present and might help to focus the molecular genetic diagnosis.<sup>48</sup>

#### DUOX

In contrast to the effects of insufficient or absent TPO or thyroglobulin activity, defects in the H<sub>2</sub>O<sub>2</sub>-generating oxidase system (DUOX2, DUOX2a) are more subtle and can appear as a transient, mild TSH elevation,<sup>49</sup> possibly due to the redundancy of different proteins in the oxidase system.

#### GNAS

Combined central and primary congenital hypothyroidism can result from mutations in the *GNAS* gene, which cause pseudohypoparathyroidism type 1a.<sup>50</sup> The underlying gene defect affects the function of the G-protein  $\alpha$ , which is crucial for TRH as well as TSH receptor signaling, leading to only mildly elevated TSH levels.<sup>51</sup> Features that are clinically suggestive of this form of congenital hypothyroidism are the associated findings of short digits and short stature and mental retardation despite adequate levothyroxine treatment.

### Clinical diagnosis

#### Signs and symptoms

Clinical symptoms of congenital hypothyroidism detected by screening in neonates are usually subtle and nonspecific. They include long-term jaundice, feeding

difficulty, lethargy, constipation, macroglossia, hypothermia, edema, wide posterior fontanel, umbilical hernia and the so-called 'hypothyroid facial appearance'.<sup>13</sup> If congenital hypothyroidism remains untreated, the clinical symptoms become evident in the second half of the first year of life, with growth retardation and a delay in motor development. In addition to the delay in the development of motor skills, intellectual disability is the most important and devastating clinical symptom of congenital hypothyroidism, as it is not reversible.

Almost 10% of neonates with congenital hypothyroidism are affected by additional congenital malformations.<sup>52</sup> Congenital heart defects are the most common, affecting 50% of patients. Congenital hypothyroidism can also occur as one obligatory feature of rare genetic syndromes, such as the Bamforth–Lazarus syndrome,<sup>29</sup> and is more frequent in children with Down syndrome<sup>53</sup> and pseudohypoparathyroidism type 1a.<sup>54</sup> Clinical symptoms of an underlying syndrome can precede the diagnosis of congenital hypothyroidism, especially in patients with the Bamforth–Lazarus syndrome, in whom cleft palate and spiky hairs are present at birth. Mild congenital hypothyroidism or elevated TSH levels are more frequent in patients with Williams–Beuren syndrome<sup>26</sup> and in those with pseudohypoparathyroidism type 1a.<sup>54</sup>

#### Cases missed by screening


Variants of congenital hypothyroidism that are characterized by an inappropriate low TSH level, such as central and preterm congenital hypothyroidism, cannot be diagnosed with TSH-based screening strategies. Because free T<sub>4</sub> measurement in dried blood spots has not been established with sufficient sensitivity and specificity so far, indirect strategies were developed to diagnose these disease variants. In the Netherlands, an elaborated approach combines the screening of total T<sub>4</sub> with measurement of TSH and thyroxine-binding globulin as a surrogate for the free T<sub>4</sub> fraction.<sup>55</sup> The results of this program clearly show that, in addition to primary congenital hypothyroidism, almost all cases of central congenital hypothyroidism can be detected, with an incidence rate of 1 in 21,000, which is close to the rate of 1 in 19,000 calculated based on the clinical diagnosis of central congenital hypothyroidism.<sup>56</sup>

Due to the immature hypothalamic–pituitary–thyroid axis in preterm neonates,<sup>57</sup> some preterm children with hypothyroidism exhibit a late rise of TSH levels and might, therefore, be missed with TSH-based screening programs. Moreover, dopamine, which is frequently used in the treatment of ill premature neonates, can attenuate TSH release.<sup>58</sup> Although these occurrences are rare,<sup>59</sup> single case reports of prematurely born patients with undiagnosed congenital hypothyroidism have led to the important recommendation to re-screen neonates born preterm before discharge from the hospital, especially those in intensive care units who received dopamine.<sup>60</sup>

#### Confirmatory diagnosis

##### Biochemical measurements

Once a child has a conspicuous result in the neonatal screening, the definite diagnosis of congenital hypothyroidism



**Figure 3** | Diagnostic algorithm for the detection of primary congenital hypothyroidism. Although evidence for the alternative steps of the diagnostic procedure in the confirmation and differential diagnosis of congenital hypothyroidism is limited, the algorithm is based on available guidelines and personal experience of the authors.

depends on a so-called ‘confirmatory diagnosis’ (Figure 3). To avoid misdiagnosis owing to a transient TSH surge or a sample error, serum measurement of TSH,  $T_4$ —either total or free  $T_4$ —and  $T_3$  is necessary before treatment can be initiated. In neonates with elevated serum TSH and low thyroid hormone levels, the diagnosis of congenital hypothyroidism is considered to be confirmed; thyroid imaging and testing for maternal thyroid antibodies is then recommended to more precisely define subgroups of congenital hypothyroidism.<sup>61,62</sup>

In patients with confirmed severe congenital hypothyroidism, serum levels of TSH >50 mU/l and low  $T_4$  or free  $T_4$  levels are present, whereas  $T_3$  values are in the lower normal range in most cases. More difficult to interpret are those values that reflect mild congenital hypothyroidism, with TSH levels <50 mU/l and normal or borderline  $T_4$  (or free  $T_4$ ) concentration. Because signs and symptoms of congenital hypothyroidism are related to decreased thyroid hormone levels and not to elevated TSH levels, it is necessary to assess whether a child is deprived of thyroid hormone or not. Interindividual  $T_4$  levels vary enormously, and the normal range of  $T_4$  and free  $T_4$  can differ by 100% (Table 1).<sup>63</sup> In addition, neonatal  $T_4$  levels change rapidly in the first days of life, and the almost twofold higher levels in the first week of life need to be considered in the assessment.<sup>63</sup> In a child with a functioning pituitary gland, an elevated but not further increasing TSH level is a good

marker indicating an individual steady-state of sufficient  $T_4$ . Treatment, therefore, does not need to be initiated as long as the serum  $T_4$  is within the normal, age-adjusted range and the TSH concentration does not further increase in repeated serum controls.

A stable, elevated TSH level with normal  $T_4$  concentration is present in at least 3% of the ‘healthy’ child population, given that the upper normal TSH level is defined by statistical means of +2SD when measuring normal control populations. Longitudinal measurements in large cohorts revealed that a TSH level <7.5 mU/l will not further increase over time.<sup>64</sup> This ‘normal’, elevated TSH level, therefore, probably reflects an inborn variant of the individual set-point of the hypothalamus–pituitary–thyroid axis and does not represent imminent pathology.

#### Imaging

As part of the confirmatory diagnosis, imaging can be employed in neonates with biochemically proven congenital hypothyroidism to define the subgroup of hypothyroid pathology (thyroid dysgenesis versus dyshormonogenesis). The technique used for imaging differs between centers and depends mostly on local experience and availability. The less invasive ultrasonography technique is sufficient to separate a structural defect from a normal or enlarged gland,<sup>5</sup> whereas only the more invasive scintigraphy—either with radioactive iodine or technetium, performed when TSH

**Table 1** | Final IQ outcome\* in children with congenital hypothyroidism treated with levothyroxine

Study	n (patients/controls)	Duration (years)	Start of treatment (days of life)	Levothyroxine dose ( $\mu\text{g}/\text{kg}$ daily)	Full-scale IQ controls	Full-scale IQ CH patients
Oerbeck <i>et al.</i> <sup>79</sup>	49/41 (siblings)	20	24.4	8.4	111.4	102.4
Rovet <i>et al.</i> <sup>78</sup>	42/42 (siblings)	6–9	12.8 (7.6–18)	3.2–12.3	108.9	102.7
Dimitropoulos <i>et al.</i> <sup>84</sup>	63/175 (normal control group)	14	9 (5–18)	14.7 (9.9–23.6)	111.4	101.7

\*Measured with the Wechsler intelligence scale. Abbreviation: CH, congenital hypothyroidism.

concentration is still high—enables an exact localization of an ectopic, lingual thyroid gland.<sup>65</sup>

To further increase the specificity in discerning subgroups of congenital hypothyroidism, thyroglobulin can be measured as a thyroid-tissue-specific marker. The discrimination of goiter versus athyrosis (lack of the thyroid gland) can easily be achieved in children by combining measurement of thyroglobulin levels and ultrasonography. However, the more subtle differentiation of apparent athyrosis from an ectopic thyroid gland—although possible in most cases of complete absence of thyroglobulin—remains difficult in some children, owing to the individual overlap of thyroglobulin levels in these conditions.<sup>66</sup> Nevertheless, as the demonstration of an ectopic gland versus athyrosis does not change the indication for or dose of levothyroxine, several pediatric centers regard ultrasonography combined with measurement of thyroglobulin levels to be sufficient and do not perform scintigraphy.

Imaging should not delay the initiation of therapy, which should start as early as possible. Scintigraphy can be combined with a perchlorate-based protocol to measure the amount of organified iodine to demonstrate a defect in thyroid hormone synthesis. However, this investigation, which is part of a scientific approach rather than clinical routine, can be postponed until a later age, when children will be off treatment for re-evaluation of the initial diagnosis in their third year of life.

#### Thyroid antibodies and iodine

In children with confirmed biochemical hypothyroidism and a normal thyroid gland on imaging, a further diagnostic step should be performed to exclude either a maternal thyroid autoimmune disease or an iodine overload as a potential cause of transient congenital hypothyroidism. Typically, maternal antibodies that can cause fetal hypothyroidism block the TSH receptor, and after clearance from the infant's circulation at an age of 6 months, thyroid function normalizes.<sup>67,68</sup> The same transient course can be expected in those rare cases of iodine overload that can result from maternal disinfection with povidone iodine before or during delivery or from a direct application of this substance to the neonate during preoperative disinfection. The transdermal resorption of high amounts of iodine leads to an inactivation of the neonatal thyroid gland (Wolff–Chaikoff effect) and sometimes causes severe but short-lasting hypothyroidism.<sup>69,70</sup> Treatment of the child is still necessary for several weeks until normal thyroid function is restored.

#### Treatment

In principle, successful treatment is achieved by application of a single oral levothyroxine dose in the morning. The choice of levothyroxine rather than liothyronine or a combination of the two is reasonable, because the biologically active liothyronine is generated by local expression of deiodinases, especially in the brain and other target tissues.<sup>71</sup> In addition, studies have shown that treatment with liothyronine is not superior in terms of final cognitive outcome.<sup>72</sup> In most countries, levothyroxine for oral application is only licensed as a tablet. In Europe, liquid preparations with a concentration of 5  $\mu\text{g}$  per drop are licensed, which allows smaller intervals of dose adjustment.<sup>73</sup>

Resorption of oral levothyroxine is excellent, and differences in individual kinetics that might exist are overcome by dose adjustment according to actual TSH levels. However, soy milk has been shown to interfere markedly with the resorption of levothyroxine to the extent that the drug's dose has to be increased after consumption of soy-rich foodstuffs.<sup>74</sup>

Owing to the long half-life of levothyroxine in the circulation, several days of administration are needed to reach a steady-state. In addition, a preliminary report in adult patients documented an at least equal, if not better, effect of levothyroxine application in the evening rather than in the morning.<sup>75</sup> The current recommendation to take levothyroxine in the morning might, therefore, need revisiting; in particular situations of low compliance, the time point of drug administration should be adapted to the individual.

#### Dose and start of treatment

Since the first introduction of screening, the optimal starting point and dose of levothyroxine have been discussed controversially. The initial doses for neonates in the first screening programs were chosen on the basis of practicability (availability of tablet preparations of levothyroxine for adults: 25.0  $\mu\text{g}$ , 50.0  $\mu\text{g}$  or 37.5  $\mu\text{g}$  as half of a 75.0  $\mu\text{g}$  tablet) and individual clinician's experience. In North America, a daily dose of 25  $\mu\text{g}$  was given,<sup>2</sup> whereas in Europe several centers administered 50  $\mu\text{g}$  per day,<sup>3</sup> resulting in individual doses of levothyroxine of 5–10  $\mu\text{g}/\text{kg}$  or 10–20  $\mu\text{g}/\text{kg}$  body weight, respectively. Irrespective of the dose, the initial results were encouraging, given that a beneficial effect, with normal growth, motor development and IQ, was found in almost all treated children.<sup>76,77</sup> However, in two studies of young adult patients diagnosed in the first screening programs

in Canada and Norway, who were treated with an initial dose of 25 µg per day, the final full-scale IQ was in the normal range, albeit consistently 6–8 points lower than that of an appropriate sibling control group.<sup>78,79</sup> This gap was argued to potentially result from an insufficient effect of the 25 µg levothyroxine dose.<sup>80</sup>

Newer, retrospective comparisons and prospective, but nonrandomized, observations revealed an improved cognitive outcome with an increased dose of levothyroxine >10 µg/kg body weight daily.<sup>80–82</sup> In addition, a randomized study comparing 37.5 µg and 50.0 µg of levothyroxine revealed a better full-scale IQ in the high-dose group compared with the low-dose group at an age of 2–8 years.<sup>83</sup> Together, these data clearly favor high levothyroxine doses (>10 µg/kg per day) to improve IQ outcome in children with congenital hypothyroidism. However, in a cohort from Switzerland, a high dose of 14.9 µg/kg body weight still resulted in a 9-points-lower full-scale IQ compared with that of a matched control group.<sup>84</sup> To date, no significant adverse effects have been reported when children are treated with high doses of levothyroxine (37.5 µg or 50 µg per day) in all studies.

Closely linked with the effect of a high versus low initial treatment dose is the question whether an early start of treatment can further improve the IQ in patients with congenital hypothyroidism. Several studies compared an early versus late start of treatment, that is, 10 days versus 16 days<sup>88</sup> and <15 days versus >21 days after birth,<sup>89</sup> which revealed a consistently better IQ in the early-treatment group. Whether an even earlier start of treatment, before the age of 10 days, will close the gap of full-scale IQ points remains to be investigated. Based on currently available outcome data, which do not reach a high level of evidence, most guidelines now recommend a high dose of levothyroxine of 10–15 µg/kg body weight with the aim to start treatment within the first 2 weeks of life.<sup>62,86</sup>

Other potential explanations for the continuously observed gap in full-scale IQ outcome might be that the fetal period of severe hypothyroidism can induce neuronal damage that cannot be compensated for by postnatal treatment. On the other hand, the remaining IQ gap might be related to the still unknown molecular pathogenesis of congenital hypothyroidism. As shown for the mental retardation in patients with FOXE1 deficiency<sup>31</sup> and for neurological defects in those with NKX2-1 deficiency,<sup>32</sup> a molecular defect that results in thyroid dysgenesis might also interfere with normal brain development. In some cases, this mechanism might lead to an unfavorable cognitive or neurological outcome despite screening for and optimal treatment of congenital hypothyroidism. Further outcome studies need to take into account probable molecular mechanisms that might interfere with normal cognitive development.

### Mild forms of congenital hypothyroidism

A current topic of discussion concerns the diagnosis and necessity for treatment of mild forms of congenital hypothyroidism in children with hyperthyropinemia. Several groups have now reported their experience with low TSH cut-off levels of 10 mU/l<sup>87,88</sup> and even 6 mU/l.<sup>89</sup> The

incidence of congenital hypothyroidism increased to 1 in 1,446<sup>87</sup> and to 1 in 1,556, respectively, using these thresholds.<sup>88</sup> This increase was accompanied by a more than 10-fold higher rate of screening TSH reinvestigations, for example, a recall rate that is in the range of 0.1–0.3% of all screened neonates when the TSH cut-off level is 15 mU/l. The majority of children with supposed congenital hypothyroidism were shown to have permanent elevated TSH levels (>5 mU/l) at 2–3 years of age,<sup>88</sup> which was argued to be proof of congenital hypothyroidism and support the need for continued treatment with levothyroxine. However, these children—who had hyperthyrotropinemia rather than ‘true’ congenital hypothyroidism—were treated without any evidence of a clinically significant benefit of treatment for their cognitive development. Nevertheless, given the devastating effect of hypothyroidism on the neonatal development of the CNS and because individual patients with mild TSH elevation might have borderline T<sub>4</sub> values,<sup>87</sup> the tendency to overtreat is easily comprehensible. Therefore, outcome studies that include a substantial number of untreated children with mild congenital hypothyroidism are urgently needed to better judge this particular treatment indication.

### Follow-up and outcome

After initiation of therapy, the usual recommendation is to monitor TSH and T<sub>4</sub> levels at weekly intervals for 1 month, at monthly intervals for 3 months, followed by a continuous follow-up every 3 months during the first 2 years of life and later every 6 months. Studies about treatment modalities during the maintenance phase have been surprisingly rare so far. One study from Brazil reported a clinically significant effect of the number of follow-up appointments on final IQ outcome.<sup>90</sup>

Congenital hypothyroidism is a chronic disease and the outcome of the affected children depends on optimal compliance of the parents and later in life of the patients themselves. As in other chronic, inherited diseases, treatment of congenital hypothyroidism and patient care is a balance of avoiding fear but maintaining a good compliance at the same time. However, congenital hypothyroidism seems to be easily treatable compared with other metabolic, inherited diseases, and a tendency to follow up children with congenital hypothyroidism in unspecialized pediatric endocrine centers exists. How these children will develop and how efficient the health-care service within this public medical domain actually is remains so far unknown. Published outcome studies of patients with congenital hypothyroidism are generated in highly specialized and closely interlinked research groups that have dedicated decades of work to the diagnosis and treatment of congenital hypothyroidism. So far, the general fate of children from a population-wide view is unknown, because only very few health-care service studies were undertaken with a focus on congenital hypothyroidism.<sup>91</sup> This fact is surprising given that congenital hypothyroidism is one of the most frequent conditions among the spectrum of rare diseases. The population-based screening programs that are now established in a large number of countries generate a yearly cohort of approximately 3,000 patients

with congenital hypothyroidism with the need for replacement therapy in the USA, Europe and Japan alone. The ongoing increase in screening sensitivity due to reductions in the TSH cut-off threshold will increase this number even further and will fuel the need to appropriately re-evaluate treatment indications in children with hyperthyrotropinemia. Obviously, further studies will focus on these aspects of health-care research in the follow-up and outcome of children with congenital hypothyroidism.

Owing to the successful treatment of children with congenital hypothyroidism, these individuals now reach an adult age and are able to lead presumably normal lives. Thus a hitherto nonexistent group of adult patients now requires adult health-care services that are educated about outcome, long-term needs and related organ-specific effects in patients with developmental defects of the thyroid gland treated with thyroid hormone replacement. Adult patients with congenital hypothyroidism are at risk of obesity,<sup>92</sup> and impaired diastolic function and increased intima-media thickness in young adult patients with congenital hypothyroidism diagnosed in screening programs were described in a study from Italy.<sup>93</sup> Together, these data clearly demonstrate the need for ongoing specialized care of adult patients with congenital hypothyroidism.

**Conclusions**

Neonatal screening for congenital hypothyroidism represents the most efficient method to prevent mental retardation and ensure normal IQ levels in this patient population. Successful replacement therapy is easily

achieved by a single, daily dose of oral levothyroxine. However, uncertainty and controversy remain regarding the appropriate starting dose. Despite several guidelines being in favor of a high dose (>10 µg/kg body weight per day), the evidence level supporting this recommendation is still low.<sup>94</sup> Moreover, the implementation of screening programs harbors the risk of overdiagnosing and overtreating a large number of children, especially with the current tendency to lower TSH cut-off levels. The more sensitive the screening programs, the higher the risk of losing the balance between their burden and benefits. Further evidence is needed to justify treatment of neonates with mild hyperthyrotropinemia as has now become routine in most programs with a reduced TSH cut-off level. In addition, the development of standardized follow-up programs for adult patients with congenital hypothyroidism, who can presumably live a normal life but are considered to be chronically ill, is a further task that needs to be addressed to optimize treatment of congenital hypothyroidism following detection by neonatal screening.

**Review criteria**

Articles cited in this Review were selected on the basis of a search of the PubMed database. Search terms were “congenital hypothyroidism” and “outcome”, “treatment”, “diagnosis” and “pathogenesis”. The literature search was not limited to certain years. Only full-text papers written in English were selected.

<p>1. Radwin, L. S., Michelson, J. P., Berman, A. B. &amp; Kramer, B. End results in treatment of congenital hypothyroidism; follow-up study of physical, mental and behavioral development. <i>Am. J. Dis. Child.</i> <b>78</b>, 821–843 (1949).</p> <p>2. Fisher, D. A. <i>et al.</i> Screening for congenital hypothyroidism: results of screening one million North American infants. <i>J. Pediatr.</i> <b>94</b>, 700–705 (1979).</p> <p>3. Illig, R. &amp; Gitzelmann, R. Screening for congenital hypothyroidism. <i>J. Pediatr.</i> <b>91</b>, 348–349 (1977).</p> <p>4. Clerc, J. <i>et al.</i> Scintigraphic imaging of paediatric thyroid dysfunction. <i>Horm. Res.</i> <b>70</b>, 1–13 (2008).</p> <p>5. Bubuteishvili, L., Gareil, C., Czernichow, P. &amp; Léger, J. Thyroid abnormalities by ultrasonography in neonates with congenital hypothyroidism. <i>J. Pediatr.</i> <b>143</b>, 759–764 (2003).</p> <p>6. Marinovic, D., Gareil, C., Czernichow, P. &amp; Léger, J. Ultrasonographic assessment of the ectopic thyroid tissue in children with congenital hypothyroidism. <i>Pediatr. Radiol.</i> <b>34</b>, 109–113 (2004).</p> <p>7. Maiorana, R. <i>et al.</i> Thyroid hemiagenesis: prevalence in normal children and effect on thyroid function. <i>J. Clin. Endocrinol. Metab.</i> <b>88</b>, 1534–1536 (2003).</p> <p>8. Klein, A. H., Meltzer, S. &amp; Kenny, F. M. Improved prognosis in congenital hypothyroidism treated before age three months. <i>J. Pediatr.</i> <b>81</b>, 912–915 (1972).</p> <p>9. Odell, W. D., Wilber, J. F. &amp; Paul, W. E. Radioimmunoassay of human thyrotropin in serum. <i>Metabolism</i> <b>14</b>, 465–467 (1965).</p> <p>10. Klein, A. H., Agustin, A. V. &amp; Foley, T. P. Jr. Successful laboratory screening for congenital hypothyroidism. <i>Lancet</i> <b>2</b>, 77–79 (1974).</p>	<p>11. Dussault, J. H. <i>et al.</i> Preliminary report on a mass screening program for neonatal hypothyroidism. <i>J. Pediatr.</i> <b>86</b>, 670–674 (1975).</p> <p>12. Fisher, D. A. &amp; Odell, W. D. Acute release of thyrotropin in the newborn. <i>J. Clin. Invest.</i> <b>48</b>, 1670–1677 (1969).</p> <p>13. Alm, J., Larsson, A. &amp; Zetterström, R. Congenital hypothyroidism in Sweden. Incidence and age at diagnosis. <i>Acta Paediatr. Scand.</i> <b>67</b>, 1–3 (1978).</p> <p>14. Jacobsen, B. B. &amp; Brandt, N. J. Congenital hypothyroidism in Denmark. <i>Arch. Dis. Child.</i> <b>56</b>, 134–136 (1981).</p> <p>15. Hulse, J. A. Outcome for congenital hypothyroidism. <i>Arch. Dis. Child.</i> <b>59</b>, 23–29 (1984).</p> <p>16. Grosse, S. D. &amp; Van Vliet, G. Prevention of intellectual disability through screening for congenital hypothyroidism: how much and at what level? <i>Arch. Dis. Child.</i> <b>96</b>, 374–379 (2011).</p> <p>17. Alm, J., Hagenfeldt, L., Larsson, A. &amp; Lundberg, K. Incidence of congenital hypothyroidism: retrospective study of neonatal laboratory screening versus clinical symptoms as indicators leading to diagnosis. <i>Br. Med. J. (Clin. Res. Ed.)</i> <b>289</b>, 1171–1175 (1984).</p> <p>18. Rastogi, M. V. &amp; LaFranchi, S. H. Congenital hypothyroidism. <i>Orphanet. J. Rare Dis.</i> <b>5</b>, 17 (2010).</p> <p>19. Stoppa-Vaucher, S., Van Vliet, G. &amp; Deladoëy, J. Variation by ethnicity in the prevalence of congenital hypothyroidism due to thyroid dysgenesis. <i>Thyroid</i> <b>21</b>, 13–18 (2011).</p> <p>20. Castanet, M. <i>et al.</i> Nineteen years of national screening for congenital hypothyroidism: familial cases with thyroid dysgenesis suggest the</p>	<p>involvement of genetic factors. <i>J. Clin. Endocrinol. Metab.</i> <b>86</b>, 2009–2014 (2001).</p> <p>21. Hinton, C. F. <i>et al.</i> Trends in incidence rates of congenital hypothyroidism related to select demographic factors: data from the United States, California, Massachusetts, New York, and Texas. <i>Pediatrics</i> <b>125</b> (Suppl. 2), S37–S47 (2010).</p> <p>22. De Felice, M. &amp; Di Lauro, R. Thyroid development and its disorders: genetics and molecular mechanisms. <i>Endocr. Rev.</i> <b>25</b>, 722–746 (2004).</p> <p>23. Léger, J. <i>et al.</i> Thyroid developmental anomalies in first degree relatives of children with congenital hypothyroidism. <i>J. Clin. Endocrinol. Metab.</i> <b>87</b>, 575–580 (2002).</p> <p>24. Perry, R. <i>et al.</i> Discordance of monozygotic twins for thyroid dysgenesis: implications for screening and for molecular pathophysiology. <i>J. Clin. Endocrinol. Metab.</i> <b>87</b>, 4072–4077 (2002).</p> <p>25. van Trotsenburg, A. S. <i>et al.</i> Trisomy 21 causes persistent congenital hypothyroidism presumably of thyroïdal origin. <i>Thyroid</i> <b>16</b>, 671–680 (2006).</p> <p>26. Stagi, S., Manoni, C., Salti, R., Cecchi, C. &amp; Chiarelli, F. Thyroid hypoplasia as a cause of congenital hypothyroidism in Williams syndrome. <i>Horm. Res.</i> <b>70</b>, 316–318 (2008).</p> <p>27. Narumi, S., Muroya, K., Asakura, Y., Adachi, M. &amp; Hasegawa, T. Transcription factor mutations and congenital hypothyroidism: systematic genetic screening of a population-based cohort of Japanese patients. <i>J. Clin. Endocrinol. Metab.</i> <b>95</b>, 1981–1985 (2010).</p> <p>28. Al Taji, E. <i>et al.</i> Screening for mutations in transcription factors in a Czech cohort of 170 patients with congenital and early-onset hypothyroidism: identification of a novel</p>
---	---	--

- PAX8 mutation in dominantly inherited early-onset non-autoimmune hypothyroidism. *Eur. J. Endocrinol.* **156**, 521–529 (2007).
29. Bamforth, J. S., Hughes, I. A., Lazarus, J. H., Weaver, C. M. & Harper, P. S. Congenital hypothyroidism, spiky hair, and cleft palate. *J. Med. Genet.* **26**, 49–51 (1989).
  30. Clifton-Bligh, R. J. *et al.* Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. *Nat. Genet.* **19**, 399–401 (1998).
  31. Castanet, M. & Polak, M. Spectrum of human Foxe1/TTF2 mutations. *Horm. Res. Paediatr.* **73**, 423–429 (2010).
  32. Krude, H. *et al.* Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. *J. Clin. Invest.* **109**, 475–480 (2002).
  33. Pohlenz, J. *et al.* Partial deficiency of thyroid transcription factor 1 produces predominantly neurological defects in humans and mice. *J. Clin. Invest.* **109**, 469–473 (2002).
  34. Carré, A. *et al.* Five new TTF1/NKX2.1 mutations in brain–lung–thyroid syndrome: rescue by PAX8 synergism in one case. *Hum. Mol. Genet.* **18**, 2266–2276 (2009).
  35. Guillot, L. *et al.* NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in “Brain–Lung–Thyroid Syndrome”. *Hum. Mutat.* **31**, E1146–E1162 (2010).
  36. Breedveld, G. J. *et al.* Mutations in TITF-1 are associated with benign hereditary chorea. *Hum. Mol. Genet.* **11**, 971–979 (2002).
  37. Dentice, M. *et al.* Missense mutation in the transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid dysgenesis. *J. Clin. Endocrinol. Metab.* **91**, 1428–1433 (2006).
  38. Macchia, P. E. *et al.* PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. *Nat. Genet.* **19**, 83–86 (1998).
  39. Meeus, L. *et al.* Characterization of a novel loss of function mutation of PAX8 in a familial case of congenital hypothyroidism with in-place, normal-sized thyroid. *J. Clin. Endocrinol. Metab.* **89**, 4285–4291 (2004).
  40. Montanelli, L. & Tonacchera, M. Genetics and phenomics of hypothyroidism and thyroid dys- and agenesis due to PAX8 and TTF1 mutations. *Mol. Cell Endocrinol.* **322**, 64–71 (2010).
  41. Biebermann, H., Grüters, A., Schöneberg, T. & Guderhann, T. Congenital hypothyroidism caused by mutations in the thyrotropin-receptor gene. *N. Engl. J. Med.* **336**, 1390–1391 (1997).
  42. Refetoff, S. Resistance to thyrotropin. *J. Endocrinol. Invest.* **26**, 770–779 (2003).
  43. Bizhanova, A. & Kopp, P. Minireview: The sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid. *Endocrinology* **150**, 1084–1090 (2009).
  44. Ris-Stalpers, C. & Bikker, H. Genetics and phenomics of hypothyroidism and goiter due to TPO mutations. *Mol. Cell Endocrinol.* **322**, 38–43 (2010).
  45. Moreno, J. C. & Visser, T. J. New phenotypes in thyroid dysmorphogenesis: hypothyroidism due to DUOX2 mutations. *Endocr. Dev.* **10**, 99–117 (2007).
  46. Medeiros-Neto, G., Targovnik, H. M. & Vassart, G. Defective thyroglobulin synthesis and secretion causing goiter and hypothyroidism. *Endocr. Rev.* **14**, 165–183 (1993).
  47. Abramowicz, M. J. *et al.* Identification of a mutation in the coding sequence of the human thyroid peroxidase gene causing congenital goiter. *J. Clin. Invest.* **90**, 1200–1204 (1992).
  48. Kopp, P., Pesce, L. & Solis-S., J. C. Pendred syndrome and iodide transport in the thyroid. *Trends Endocrinol. Metab.* **19**, 260–268 (2008).
  49. Hului, I. *et al.* A single copy of the recently identified dual oxidase maturation factor (DUOXA) 1 gene produces only mild transient hypothyroidism in a patient with a novel biallelic DUOXA2 mutation and monoallelic DUOXA1 deletion. *J. Clin. Endocrinol. Metab.* **96**, E841–E845 (2011).
  50. Pinsker, J. E., Rogers, W., McLean, S., Schaefer, F. V. & Fenton, C. Pseudohypoparathyroidism type 1a with congenital hypothyroidism. *J. Pediatr. Endocrinol. Metab.* **19**, 1049–1052 (2006).
  51. Beck-Peccoz, P. *et al.* Syndromes of hormone resistance in the hypothalamic–pituitary–thyroid axis. *Best Pract. Res. Clin. Endocrinol. Metab.* **20**, 529–546 (2006).
  52. Olivieri, A. *et al.* A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism: data from the Italian Registry for Congenital Hypothyroidism (1991–1998). *J. Clin. Endocrinol. Metab.* **87**, 557–562 (2002).
  53. Cutler, A. T., Benezra-Obeiter, R. & Brink, S. J. Thyroid function in young children with Down syndrome. *Am. J. Dis. Child.* **140**, 479–483 (1986).
  54. Weisman, Y., Golander, A., Spierer, Z. & Farfel, Z. Pseudohypoparathyroidism type 1a presenting as congenital hypothyroidism. *J. Pediatr.* **107**, 413–415 (1985).
  55. Kempers, M. J. *et al.* Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin measurement: potentials and pitfalls. *J. Clin. Endocrinol. Metab.* **91**, 3370–3376 (2006).
  56. Hanna, C. E. *et al.* Detection of congenital hypopituitary hypothyroidism: ten-year experience in the Northwest Regional Screening Program. *J. Pediatr.* **109**, 959–964 (1986).
  57. Fisher, D. A. Thyroid function and dysfunction in premature infants. *Pediatr. Endocrinol. Rev.* **4**, 317–328 (2007).
  58. Filippi, L., Pezzati, M., Cecchi, A. & Poggi, C. Dopamine infusion: a possible cause of undiagnosed congenital hypothyroidism in preterm infants. *Pediatr. Crit. Care Med.* **7**, 249–251 (2006).
  59. Vincent, M. A., Rodd, C., Dussault, J. H. & Van Vliet, G. Very low birth weight neonates do not need repeat screening for congenital hypothyroidism. *J. Pediatr.* **140**, 311–314 (2002).
  60. Kugelman, A., Riskin, A., Bader, D. & Koren, I. Pitfalls in screening programs for congenital hypothyroidism in premature neonates. *Am. J. Perinatol.* **26**, 383–385 (2009).
  61. Toubanc, J. E. Guidelines for neonatal screening programs for congenital hypothyroidism. Working Group for Neonatal Screening in Paediatric Endocrinology of the European Society for Paediatric Endocrinology. *Acta Paediatr. Suppl.* **88**, 13–14 (1999).
  62. Rose, S. R. *et al.* Update of newborn screening and therapy for congenital hypothyroidism. *Pediatrics* **117**, 2290–2303 (2006).
  63. Elmlinger, M. W., Kühnel, W., Lambrecht, H. G. & Ranke, M. B. Reference intervals from birth to adulthood for serum thyroxine (T4), triiodothyronine (T3), free T3, free T4, thyroxine binding globulin (TBG) and thyrotropin (TSH). *Clin. Chem. Lab. Med.* **39**, 973–979 (2001).
  64. Lazar, L. *et al.* Natural history of thyroid function tests over 5 years in a large pediatric cohort. *J. Clin. Endocrinol. Metab.* **94**, 1678–1682 (2009).
  65. Schoen, E. J., Clapp, W., To, T. T. & Fireman, B. H. The key role of newborn thyroid scintigraphy with isotopic iodide (<sup>123</sup>I) in defining and managing congenital hypothyroidism. *Pediatrics* **114**, e683–e688 (2004).
  66. Muir, A., Daneman, D., Daneman, A. & Ehrlich, R. Thyroid scanning, ultrasound, and serum thyroglobulin in determining the origin of congenital hypothyroidism. *Am. J. Dis. Child.* **142**, 214–216 (1988).
  67. Brown, R. S. *et al.* Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor-blocking antibodies in over one million babies. *J. Clin. Endocrinol. Metab.* **81**, 1147–1151 (1996).
  68. Mengreli, C. *et al.* Transient congenital hypothyroidism due to maternal autoimmune thyroid disease. *Hormones (Athens)* **2**, 113–119 (2003).
  69. Gruters, A., l’Allemand, D., Heidemann, P. H. & Schürnbrand, P. Incidence of iodine contamination in neonatal transient hyperthyrotropinemia. *Eur. J. Pediatr.* **140**, 299–300 (1983).
  70. Nishiyama, S. *et al.* Transient hypothyroidism or persistent hyperthyrotropinemia in neonates born to mothers with excessive iodine intake. *Thyroid* **14**, 1077–1083 (2004).
  71. Bernal, J. Thyroid hormones and brain development. *Vitam. Horm.* **71**, 95–122 (2005).
  72. Cassio, A. *et al.* Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine? *Pediatrics* **111**, 1055–1060 (2003).
  73. von Happe, J. H., Krude, H., l’Allemand, D., Schnabel, D. & Grüters, A. The use of L-T4 as liquid solution improves the practicability and individualized dosage in neonates and infants with congenital hypothyroidism. *J. Pediatr. Endocrinol. Metab.* **17**, 967–974 (2004).
  74. Conrad, S. C., Chiu, H. & Silverman, B. L. Soy formula complicates management of congenital hypothyroidism. *Arch. Dis. Child.* **89**, 37–40 (2004).
  75. Bolk, N., Visser, T. J., Kalsbeek, A., van Domburg, R. T. & Berghout, A. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. *Clin. Endocrinol. (Oxf.)* **66**, 43–48 (2007).
  76. Hrytsiuk, I., Gilbert, R., Logan, S., Pindoria, S. & Brook, C. G. Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review. *Arch. Pediatr. Adolesc. Med.* **156**, 485–491 (2002).
  77. Léger, J., Larroque, B. & Norton, J. Influence of severity of congenital hypothyroidism and adequacy of treatment on school achievement in young adolescents: a population-based cohort study. *Acta Paediatr.* **90**, 1249–1256 (2001).
  78. Rovet, J. F. Children with congenital hypothyroidism and their siblings: do they really differ? *Pediatrics* **115**, e52–e57 (2005).
  79. Oerbeck, B., Sundet, K., Kase, B. F. & Heyerdahl, S. Congenital hypothyroidism: influence of disease severity and L-thyroxine treatment on intellectual, motor, and school-associated outcomes in young adults. *Pediatrics* **112**, 923–930 (2003).
  80. Dubuis, J. M. *et al.* Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. *J. Clin. Endocrinol. Metab.* **81**, 222–227 (1996).
  81. Salerno, M. *et al.* Effect of different starting doses of levothyroxine on growth and intellectual outcome at four years of age in congenital hypothyroidism. *Thyroid* **12**, 45–52 (2002).
  82. Bongers-Schokking, J. J. & de Muinck Keizer-Schrama, S. M. Influence of timing and dose of

- thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidism. *J. Pediatr.* **147**, 768–774 (2005).
83. Selva, K. A., Harper, A., Downs, A., Blasco, P. A. & Lafranchi, S. H. Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. *J. Pediatr.* **147**, 775–780 (2005).
  84. Dimitropoulos, A. *et al.* Children with congenital hypothyroidism: long-term intellectual outcome after early high-dose treatment. *Pediatr. Res.* **65**, 242–248 (2009).
  85. Boileau, P., Bain, P., Rives, S. & Toublanc, J. E. Earlier onset of treatment or increment in LT4 dose in screened congenital hypothyroidism: which as the more important factor for IQ at 7 years? *Horm. Res.* **61**, 228–233 (2004).
  86. Grüters, A. & Krude, H. Update on the management of congenital hypothyroidism. *Horm. Res.* **68** (Suppl. 5), 107–111 (2007).
  87. Corbetta, C. *et al.* A 7-year experience with low blood TSH cutoff levels for neonatal screening reveals an unsuspected frequency of congenital hypothyroidism (congenital hypothyroidism). *Clin. Endocrinol. (Oxf.)* **71**, 739–745 (2009).
  88. Mengreli, C. *et al.* Screening for congenital hypothyroidism: the significance of threshold limit in false-negative results. *J. Clin. Endocrinol. Metab.* **95**, 4283–4290 (2010).
  89. Korada, S. M. *et al.* Difficulties in selecting an appropriate neonatal thyroid stimulating hormone (TSH) screening threshold. *Arch. Dis. Child.* **95**, 169–173 (2010).
  90. Kreisner, E., Schermann, L., Camargo-Neto, E. & Gross, J. L. Predictors of intellectual outcome in a cohort of Brazilian children with congenital hypothyroidism. *Clin. Endocrinol. (Oxf.)* **60**, 250–255 (2004).
  91. Kemper, A. R., Ouyang, L. & Grosse, S. D. Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data. *BMC Pediatr.* **10**, 9 (2010).
  92. Wong, S. C., Ng, S. M. & Didi, M. Children with congenital hypothyroidism are at risk of adult obesity due to early adiposity rebound. *Clin. Endocrinol. (Oxf.)* **61**, 441–446 (2004).
  93. Salerno, M. *et al.* Long-term cardiovascular effects of levothyroxine therapy in young adults with congenital hypothyroidism. *J. Clin. Endocrinol. Metab.* **93**, 2486–2491 (2008).
  94. Ng, S. M., Anand, D. & Weindling, A. M. High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. *Cochrane Database of Systematic Reviews*, Issue 1. Art. No.: CD006972. doi:10.1002/14651858.CD006972.pub2 (2009).

#### Author contributions

Both authors contributed equally to all aspects of the article.